Loading...
Achievement of complete remission and undetectable minimal residual disease (MRD) status following induction immunochemotherapy is associated with improved outcomes for patients with mantle cell lymphoma (MCL). Investigators now report long-term follow-up of the European MCL Elderly Trial in which 560 patients ≥60 years who were not eligible for autologous stem cell transplant consolidation were randomized to either R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 8 cycles or R-FC (rituximab, fludarabine, cyclophosphamide) for 6 cycles; patients with complete or partial remission were then randomized to either maintenance rituximab or interferon-alpha (NEJM JW Oncol Hematol Aug 21 2012 and N Engl J Med 2012; 36…